EU orphan designations
Every medicine the European Commission has designated as an orphan medicine for a rare disease, on the EMA's recommendation, with its current status.
Matching designations
5 matches| Substance | Intended use | Status | Designated |
|---|---|---|---|
| treprostinil sodium EU/3/22/2588 5 clinical trials → |
Treatment of idiopathic pulmonary fibrosis | Active (positive) | 16 Mar 2022 |
| treprostinil sodium EU/3/13/1103 · now authorised as Trepulmix 5 clinical trials → |
Treatment of chronic thromboembolic pulmonary hypertension | Active (positive) | 8 Feb 2013 |
| treprostinil diethanolamine EU/3/09/635 |
Treatment of systemic sclerosis | Active (positive) | 15 May 2009 |
| treprostinil diethanolamine EU/3/05/310 · now authorised as Orepaxam |
Treatment of pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension | Active (positive) | 26 Aug 2005 |
| treprostinil sodium EU/3/04/197 · now authorised as Tyvaso; Tyvaso 5 clinical trials → |
Treatment of pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension | Active (positive) | 14 Apr 2004 |
How this page is built
Every row is copied from the EMA's orphan designations data, reproduced with acknowledgement of the source. Each substance links to its official EMA page.
- EMA orphan designations data (JSON report) ↗ active substance, intended use, EU designation number, date of designation, status and the link to each designation page
A daily job downloads the EMA's orphan designations JSON report and lists every designation, newest first. No AI drafting and no editorial pass. See our editorial standards. The the EMA data on this page was last retrieved on 10 Nov 2026. How every register is built: methodology · fixes we have made: corrections log.